Platinum Investment Management Ltd. Sells 34,884 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Platinum Investment Management Ltd. trimmed its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 28.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 87,874 shares of the company’s stock after selling 34,884 shares during the period. Structure Therapeutics accounts for 1.4% of Platinum Investment Management Ltd.’s portfolio, making the stock its 15th largest position. Platinum Investment Management Ltd. owned 0.14% of Structure Therapeutics worth $6,112,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. State of Wyoming bought a new position in shares of Structure Therapeutics in the 2nd quarter worth $28,000. EverSource Wealth Advisors LLC raised its position in shares of Structure Therapeutics by 530.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after acquiring an additional 901 shares in the last quarter. CWM LLC raised its position in shares of Structure Therapeutics by 35.2% in the 4th quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after acquiring an additional 125 shares in the last quarter. ANTIPODES PARTNERS Ltd raised its position in shares of Structure Therapeutics by 39.1% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock worth $114,000 after acquiring an additional 1,146 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Structure Therapeutics during the 2nd quarter worth $129,000. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Stock Performance

Structure Therapeutics stock opened at $42.93 on Friday. The business’s 50-day simple moving average is $43.64 and its two-hundred day simple moving average is $57.18. The company has a market cap of $3.05 billion, a PE ratio of -49.34 and a beta of -1.35. Structure Therapeutics Inc. Sponsored ADR has a fifty-two week low of $15.80 and a fifty-two week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.04. As a group, analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

GPCR has been the topic of several research analyst reports. Leerink Partners restated an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. William Blair restated an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. HC Wainwright dropped their target price on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research note on Thursday. Canaccord Genuity Group initiated coverage on Structure Therapeutics in a research note on Monday, April 27th. They set a “buy” rating and a $101.00 target price on the stock. Finally, Wolfe Research initiated coverage on Structure Therapeutics in a research note on Thursday, March 26th. They set a “peer perform” rating on the stock. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $106.75.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.